MX2016011881A - Medicamento de peptido en polvo seco. - Google Patents
Medicamento de peptido en polvo seco.Info
- Publication number
- MX2016011881A MX2016011881A MX2016011881A MX2016011881A MX2016011881A MX 2016011881 A MX2016011881 A MX 2016011881A MX 2016011881 A MX2016011881 A MX 2016011881A MX 2016011881 A MX2016011881 A MX 2016011881A MX 2016011881 A MX2016011881 A MX 2016011881A
- Authority
- MX
- Mexico
- Prior art keywords
- dry
- medicament
- peptide medicament
- powder peptide
- powder
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Se describe un medicamento de péptido en polvo seco con una concentración no típica de excipiente de carbohidrato, así como también el medicamento para usarse en tratamiento o prevención de una enfermedad o afección, así como también métodos para fabricar el medicamento.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14160540 | 2014-03-18 | ||
PCT/EP2015/055481 WO2015140125A2 (en) | 2014-03-18 | 2015-03-17 | Dry-powder peptide medicament |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016011881A true MX2016011881A (es) | 2016-12-05 |
Family
ID=50342194
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016011881A MX2016011881A (es) | 2014-03-18 | 2015-03-17 | Medicamento de peptido en polvo seco. |
Country Status (13)
Country | Link |
---|---|
US (1) | US10925924B2 (es) |
EP (1) | EP3062772B1 (es) |
JP (1) | JP6397984B2 (es) |
KR (1) | KR102316762B1 (es) |
CN (1) | CN106456707B (es) |
AU (1) | AU2015233635B2 (es) |
CA (1) | CA2940351A1 (es) |
DK (1) | DK3062772T3 (es) |
EA (1) | EA034620B1 (es) |
ES (1) | ES2665180T3 (es) |
IL (1) | IL247551B (es) |
MX (1) | MX2016011881A (es) |
WO (1) | WO2015140125A2 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015132294A1 (en) * | 2014-03-04 | 2015-09-11 | Apeptico Forschung Und Entwicklung Gmbh | Attenuation of intrapulmonary inflammation |
MX2016011881A (es) | 2014-03-18 | 2016-12-05 | Apeptico Forschung & Entwicklung Gmbh | Medicamento de peptido en polvo seco. |
WO2018211474A1 (en) | 2017-05-19 | 2018-11-22 | Trudell Medical International | Positive expiratory pressure device |
USD874064S1 (en) | 2018-05-18 | 2020-01-28 | Trudell Medical International | Mask |
USD903097S1 (en) | 2018-05-18 | 2020-11-24 | Trudell Medical International | Mask |
USD893806S1 (en) | 2018-11-09 | 2020-08-18 | Trudell Medical Internationl | Mask and shroud |
DK4051307T5 (da) | 2020-05-08 | 2024-07-22 | Apeptico Forschung & Entwicklung Gmbh | Peptid til forebyggelse eller behandling af covid-19 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4069819A (en) | 1973-04-13 | 1978-01-24 | Societa Farmaceutici S.P.A. | Inhalation device |
IT1228459B (it) | 1989-02-23 | 1991-06-19 | Phidea S R L | Inalatore con svuotamento regolare e completo della capsula. |
US5891679A (en) | 1993-02-03 | 1999-04-06 | N.V. Innogenetics S.A. | TNF-alpha muteins and a process for preparing them |
ATE212220T1 (de) * | 1996-01-24 | 2002-02-15 | Byk Gulden Lomberg Chem Fab | Verfahren zur herstellung von pulverförmigen lungensurfactant-zubereitungen |
CN1181886C (zh) | 1998-08-14 | 2004-12-29 | 基因创新有限公司 | Tnf来源的肽在治疗水肿中的应用 |
ES2316632T3 (es) * | 2001-12-05 | 2009-04-16 | Circassia Limited | Metodos y sistemas inmunoterapeuticos. |
US8236750B2 (en) * | 2004-08-06 | 2012-08-07 | Nycomed Gmbh | Composition comprising a pulmonary surfactant and a TNF-derived peptide |
MX2008013216A (es) * | 2006-04-14 | 2008-10-27 | Mannkind Corp | Formulaciones farmaceuticas de peptido-1 tipo glucagon (glp-1). |
EP2009023A1 (en) | 2007-06-04 | 2008-12-31 | Rentschler Beteiligungs GmbH | Novel peptides and their use for the treatment of edema |
AT507953B1 (de) | 2009-03-05 | 2011-02-15 | Apeptico Forschung & Entwicklung Gmbh | Verfahren zur vermeidung und zur behandlung einer hyperpermeabilität |
PL2397151T3 (pl) | 2010-06-21 | 2015-10-30 | Apeptico Forschung & Entwicklung Gmbh | Leczenie powikłań naczyniowych cukrzycy |
US9616097B2 (en) * | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
AT510585B1 (de) * | 2010-11-18 | 2012-05-15 | Apeptico Forschung & Entwicklung Gmbh | Zusammensetzung umfassend ein peptid und ein hemmstoff der viralen neuraminidase |
EP2679239A1 (de) * | 2012-06-28 | 2014-01-01 | Apeptico Forschung und Entwicklung GmbH | Pharmazeutische Zusammensetzung zur Behandlung der durch Sauerstoffarmut und verringerten Luftdruck vermittelten pulmonalen Form der Höhenkrankheit |
MX2016011881A (es) | 2014-03-18 | 2016-12-05 | Apeptico Forschung & Entwicklung Gmbh | Medicamento de peptido en polvo seco. |
-
2015
- 2015-03-17 MX MX2016011881A patent/MX2016011881A/es unknown
- 2015-03-17 JP JP2017500407A patent/JP6397984B2/ja active Active
- 2015-03-17 WO PCT/EP2015/055481 patent/WO2015140125A2/en active Application Filing
- 2015-03-17 DK DK15711471.1T patent/DK3062772T3/en active
- 2015-03-17 KR KR1020167024513A patent/KR102316762B1/ko active IP Right Grant
- 2015-03-17 US US15/126,794 patent/US10925924B2/en active Active
- 2015-03-17 EA EA201691860A patent/EA034620B1/ru unknown
- 2015-03-17 CN CN201580014154.9A patent/CN106456707B/zh active Active
- 2015-03-17 ES ES15711471.1T patent/ES2665180T3/es active Active
- 2015-03-17 EP EP15711471.1A patent/EP3062772B1/en active Active
- 2015-03-17 AU AU2015233635A patent/AU2015233635B2/en not_active Ceased
- 2015-03-17 CA CA2940351A patent/CA2940351A1/en not_active Abandoned
-
2016
- 2016-08-30 IL IL247551A patent/IL247551B/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
KR102316762B1 (ko) | 2021-10-26 |
EA034620B1 (ru) | 2020-02-27 |
WO2015140125A3 (en) | 2016-02-25 |
AU2015233635B2 (en) | 2019-07-25 |
IL247551B (en) | 2019-08-29 |
CN106456707A (zh) | 2017-02-22 |
CN106456707B (zh) | 2020-08-11 |
EP3062772B1 (en) | 2018-01-24 |
AU2015233635A1 (en) | 2016-09-15 |
US10925924B2 (en) | 2021-02-23 |
KR20160132021A (ko) | 2016-11-16 |
EA201691860A1 (ru) | 2017-03-31 |
JP6397984B2 (ja) | 2018-09-26 |
CA2940351A1 (en) | 2015-09-24 |
ES2665180T3 (es) | 2018-04-24 |
WO2015140125A2 (en) | 2015-09-24 |
DK3062772T3 (en) | 2018-03-26 |
JP2017510633A (ja) | 2017-04-13 |
EP3062772A2 (en) | 2016-09-07 |
US20170087207A1 (en) | 2017-03-30 |
IL247551A0 (en) | 2016-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2016011881A (es) | Medicamento de peptido en polvo seco. | |
MX2022001105A (es) | Anticuerpos anti tigit. | |
GB2544906B (en) | Devices for treating vestibular and other medical impairments. | |
PH12015502773A1 (en) | Methods for treating or preventing opthalmological conditions | |
PH12015502042B1 (en) | Use of linagliptin in cardio-and renoprotective antidiabetic therapy | |
PH12017500933A1 (en) | Sublingual administration of riluzole | |
PH12017500934A1 (en) | Sublingual formulation of riluzole | |
PH12017500747B1 (en) | Heterocyclic compound | |
DK3516965T1 (da) | A fish feed and method for smoltification and prevention of desmoltification in salmonidae, and for prophylaxis and treatment of haemorrhagic smolt syndrome (hss) in salmonidae | |
CY1121566T1 (el) | Νευροπροστατευτικο και ενδειξη αυτου | |
PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
MX2019000677A (es) | Células miméticas de células b. | |
MX2016003293A (es) | Metodos y composiciones para el tratamiento de una infeccion por clamidia y enfermedades y trastornos relacionados. | |
MX2015013755A (es) | Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis. | |
MY198753A (en) | Treatment of androgen deprivation therapy associated symptoms | |
SG10201903630UA (en) | Iminosugars useful for the treatment of viral diseases | |
MA40574A (fr) | Traitement de maladies fibrotiques | |
TN2016000064A1 (en) | Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the prevention and treatment of diabetes | |
UA107743C2 (ru) | Способ лечения аденокарциномы | |
PH12014000104A1 (en) | Therapeutic methods and compositions for treating diabetes | |
EA201692164A1 (ru) | Лекарственное средство для лечения пациентов с тиннитусом | |
MX2016010919A (es) | 4-bencilsulfonil-2-butenonitrilo. | |
IN2014DE00818A (es) | ||
IN2013MU03855A (es) |